The purpose of this study is to determine the safety, tolerability, and maximal tolerated
dose (MTD) of the combination of Abemaciclib and Sunitinib administered orally in patients
with advanced and metastatic renal cell carcinoma. This study consists of two parts: Dose
Escalation and Dose Expansion. During the dose escalation phase, participants will be
sequentially enrolled in a standard 3 x 3 dose escalation study design to receive oral
Abemaciclib in Combination with Sunitinib. The purpose of this dose escalation is to
determine the maximal tolerated dose based on assessment of any dose limiting toxicity. The
Dose Expansion Phase will enroll additional participants at the established maximal tolerated
dose to further evaluate safety, tolerability, as well as the pharmacokinetics and
pharmacodynamics of this combination drug regimen.
Renal cell carcinoma (RCC) accounted for about 64, 000 new cancer diagnoses in the USA in
2018. Up to 30% of those diagnoses will be patients with metastatic disease. Additionally, up
to 50% of patients who undergo partial or radical nephrectomy will develop metastatic
disease.. There is no cure for metastatic RCC, thus, metastatic RCC represents a significant
cancer burden. Numerous directed therapies are available to improve overall survival but
these do not result in durable complete responses. However, recent pre-clinical studies of
RCC have demonstrated that Abemaciclib, a CDK4/6 and PIM1 kinase inhibitor, induces rapid,
dramatic, and sustained tumor regression when used in combination with Sunitinib.
Our objectives for this study are as follows:
Primary Objectives:
- Determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of
the combination of Abemaciclib with Sunitinib for patients with metastatic renal cell
carcinoma. Additionally, determine pharmacokinetics (serum trough levels) of Abemaciclib
and Sunitinib at steady state.
- Continued safety assessment of the combination of Abemaciclib and Sunitinib at the
established maximum tolerated dose (i.e. the recommended Phase II dose)
Secondary Objectives:
Determine any anti-tumor activity in the dose expansion phase of the study. Tumor related
activity will be assessed by:
- Length of progression free survival
- Disease response rate
- Time to disease response
- Disease control rate
- Duration of response
- Overall survival and progression free survival
Inclusion Criteria:
1. Has histologic or cytologic evidence of metastatic renal cell carcinoma with histology
predominantly (>50%) clear cell renal cell carcinoma solid neoplasm.
2. Has evidence of metastatic disease. Intermediate and poor risk patients according to
International Metastatic Renal Cell Carcinoma Database criteria (IMDC) must have
received prior combination ipilimumab and nivolumab therapy and subsequently
experienced disease progression, or been offered ipilimumab and nivolumab combination
therapy and refused, or be ineligible for combination ipilimumab and nivolumab
therapy. Patients with favorable risk disease have no eligibility requirement for
prior use of ipilimumab and nivolumab immunotherapy.
3. Intermediate and poor risk patients (according to IMDC criteria) must also have
received prior cabozantinib therapy and subsequently experienced disease progression,
or been offered cabozantinib therapy and refused, or be ineligible for cabozantinib
therapy. Patients with favorable risk disease have no eligibility requirement for
prior use of cabozantinib. Cytoreductive nephrectomy is allowed but not mandatory.
4. Has in the opinion of the investigator, a predicted life expectancy of more than 3
months.
5. Has presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.
This is defined in at least one dimension as ≥20 mm with conventional techniques or as
≥10 mm with spiral CT, MRI or calipers by clinical exam
6. Has either archival tissue for analysis or will require confirmation of disease with
fresh biopsy. Tissue will not be required pre/post treatment for biomarker analysis.
7. Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2.
8. Patients with central nervous system metastases must have received surgical and/or
radiation treatment, the metastases must be neurologically stable, and patients must
be off corticosteroids or receiving a stable low-dose regimen of corticosteroids
(i.e., a daily dose of 10 mg or less of prednisone or equivalent) for at least 4 weeks
prior to the first dose of study drug.
9. Has completed any prior anticancer treatment and must have recovered from any acute
toxicities. The period between the last dose of prior treatment and the first dose of
study drug treatment must be at least 1 week for radiotherapy, at least 3-4 weeks from
prior VEGFR/mTOR/ or immunotherapy or any other tyrosine kinase inhibitor (TKI)
therapy, and at least 4 weeks for treatment with investigational drugs
10. Must be able to swallow capsules and tablets.
11. Has adequate organ function (i.e. lung, liver, kidney, bone marrow), as evidenced by
multiple laboratory value results within specific parameters.
12. Women of childbearing potential (WOCP) as defined as not surgically sterile or not
postmenopausal) must have a negative result for a serum pregnancy test before study
drug administration on cycle 1 day 1. WOCP must use a medically accepted method of
contraception and must agree to continue use this method for the duration of the study
and for 30 days after discontinuation of study drug.
13. If male, is surgically sterile, or, if capable of producing offspring, is currently
using an approved method of birth control and agrees to continued use of this method
for the duration of the study (and for 30 days after taking the last dose of study
drug because of the possible effects on spermatogenesis).
Exclusion Criteria:
1. Predominately non-clear cell renal cell carcinoma histology (i.e. >50%)
2. Has had chemotherapy within 4 weeks or radiotherapy within 1 week prior to first dose
of study drug or those who have not recovered from toxicities due to agents
administered more than 4 weeks earlier.
3. Has ongoing or active infection requiring parenteral antibiotics.
4. Has uncontrolled hypertension despite adequate therapy (i.e., systolic blood pressure
higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2
separate occasions separated by 1 week).
5. Has diabetes mellitus with occurrence of more than 2 episodes of ketoacidosis in the
12 months prior to the first dose of study drug.
6. Has an active second malignancy other than curatively resected basal cell carcinoma of
the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or
other cancers for which they are treated with curative intent, and no known active
disease in the 3 years prior to enrollment.
7. Has a primary brain tumor or has brain metastases from a non-renal cell cancer.
8. Has a QTcF interval greater than 470 msec, has a known history of QTcF prolongation,
or has a history of torsade de pointes.
9. Has a known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
10. Has a known history of pulmonary fibrosis or any other restrictive lung disorder.
11. Has any other concurrent conditions including a medical, psychiatric, or social
condition that, in the opinion of the investigator, could preclude the patient's
participation in the study, pose an undue medical hazard, or interfere with the
interpretation of the study results, including, but not limited to, patients with
congestive heart failure (New York Heart Association [NYHA] Class III or IV), cardiac
arrhythmia, or acute coronary syndromes within 6 months of enrollment.
12. Has used an investigational drug within 4 weeks prior to first dose of study drug or
is currently participating in another investigational study.
13. Has any disorder that may interfere with drug absorption, distribution, metabolism, or
excretion (including gastrointestinal surgery or bariatric surgery).
14. Has a history of allergic reactions attributed to compounds of similar chemical or
biologic composition to Abemaciclib or Sunitinib.
15. Has previous use of a CDK4/6 kinase inhibitor (eg. ribociclib, palbociclib)
16. Has previous use of a PIM1 kinase inhibitor
